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Epstein-Barr virus (EBV) has been associatedwithmultiple sclerosis (MS), however, most studies examining the
relationship between the virus and the disease have been based on serologies, and if EBV is linked to MS,CD8+
T cells are likely to be involved as they are important both in MS pathogenesis and in controlling viruses.
We hypothesized that valuable information on the link between MS and EBV would be ascertained from the
study of frequency and activation levels of EBV-specific CD8+ T cells in different categories of MS patients and
control subjects.We investigated EBV-specific cellular immune responses using proliferation and enzyme linked
immunospot assays, and humoral immune responses by analysis of anti-EBVantibodies, in a cohort of 164 sub-
jects, including 108 patients with different stages of MS, 35 with other neurological diseases and 21 healthy con-
trol subjects. Additionally, the cohort were all tested against cytomegalovirus (CMV), another neurotropic
herpes virus not convincingly associated with MS, nor thought to be deleterious to the disease.We corrected
all data for age using linear regression analysis over the total cohorts of EBV- and CMV-infected subjects.
In the whole cohort, the rate of EBV and CMV infections were 99% and 51%, respectively. The frequency of
IFN-c secreting EBV-specific CD8+ T cells in patients with clinically isolated syndrome (CIS) was significantly
higher than that found in patients with relapsing^remitting MS (RR-MS), secondary-progressive MS, primary-
progressive MS, patients with other neurological diseases and healthy controls.The shorter the interval between
MS onset and our assays, the more intense was the EBV-specific CD8+ T-cell response. Confirming the above
results, we found that EBV-specific CD8+ T-cell responses decreased in12/13 patients with CIS followed prospec-
tively for 1.0 0.2 years. In contrast, there was no difference between categories for EBV-specific CD4+ T cell,
or for CMV-specific CD4+ and CD8+ T-cell responses. Anti-EBV-encoded nuclear antigen-1 (EBNA-1)-specific
antibodies correlated with EBV-specific CD8+ T cells in patients with CIS and RR-MS.However, whereas EBV-
specific CD8+ T cells were increased the most in early MS, EBNA-1-specific antibodies were increased in early
as well as in progressive forms of MS.Our data show high levels of CD8+ T-cell activation against EBVçbut not
CMVçearly in the course of MS, which support the hypothesis that EBVmight be associated with the onset
of this disease.
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Abbreviations: EBV=Epstein-Barr virus; MS=multiple sclerosis; EBNA-1=EBV-encoded nuclear antigen-1; EA=early
antigen; LMP2= latent membrane protein-2; CMV=cytomegalovirus; CIS=clinically isolated syndrome;
RR-MS=relapsing-remitting MS; SP-MS=secondary-progressive MS; PP-MS=primary-progressive MS; MRI=magnetic
resonance imaging; IEF= isoelectric focusing; HLA=Human leucocyte antigen; PBMC=peripheral blood mononuclear cells;
ICS= intracellular cytokine staining assay; ELISPOT=enzyme linked immunospot; PHA-L=phyto-hemagglutinin lectin;
SFC=spot-forming cells; PAs=proliferation assays; SI= stimulation index; cpm=counts per minute; ELISA=enzyme-linked
immunosorbent assay; AU=arbitrary units; MBP=myelin basic protein; MOG=myelin oligodendrocyte glycoprotein
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Introduction
The g-herpesvirus Epstein-Barr virus (EBV) has consistently
been associated with multiple sclerosis (MS) (Ascherio and
Munger, 2007). Seroepidemiological studies have demon-
strated that about 100% of adult MS patients are infected
with EBV in contrast to 95.8% of age-matched healthy con-
trol subjects and two independent studies found a signif-
icantly higher rate of EBV infection (about 88%) in
children with MS as compared to healthy age-matched
children (about 50%) (Alotaibi et al., 2004; Pohl et al.,
2006). Cepok and colleagues detected the presence of anti-
EBV-encoded nuclear antigen-1 (EBNA-1) and anti-BRRF2
IgG in the CSF of MS patients, but not of patients with
other neurological diseases (Cepok et al., 2005). In addi-
tion, meta-analyses have shown that patients suffering
from EBV-related infectious mononucleosis carry a higher
risk of developing MS—in average 10 years after infec-
tion—compared to asymptomatic EBV-infected carriers
(Goldacre et al., 2004; Thacker et al., 2006; Ascherio and
Munger, 2007).
Elevated titers of anti-EBNA-1-specific IgG have been
associated with an increased risk of subsequent development
of MS (Ascherio et al., 2001; Sundstrom et al., 2004; Levin
et al., 2005; DeLorenze et al., 2006). Others have found that
there is a correlation between EBV reactivation—as measured
by early antigen (EA)-specific antibodies—and disease
activity of MS patients, as estimated by the number of
relapses and progression of Kurtzke Expanded Disability
Status Scores (Wandinger et al., 2000). Thus, although
current knowledge supports an association between EBV
and MS, it is not clear whether the virus is in fact a trigger
for the disease.
Most studies examining the relationship between EBV
and MS have been based on serologies. Studies on the
cellular immune response are scarce: EBV latent protein-
specific T cells (EBNA-1-specific CD4+ and EBNA-3A- and
latent membrane protein-2 (LMP2)-specific CD8+) were
detected more often in the blood of MS patients as com-
pared to healthy EBV-infected controls (Hollsberg et al.,
2003; Cepok et al., 2005; Lunemann et al., 2006). CD4+ T
cells from the CSF of MS patients recognized autologous B
cells transformed with EBV (Holmoy and Vartdal, 2004).
Yet, if EBV plays a role in the pathogenesis of MS, one has
to postulate that EBV-specific CD8+ T cells are likely to be
involved. Indeed, these cells are important in controlling
viruses infections, often appearing earlier than virus-specific
antibodies (Barouch and Letvin, 2001), and increasing
rapidly after viral reactivation (Du Pasquier et al., 2004).
In parallel, several elements suggest that CD8+ T cells are
involved in MS (Hemmer et al., 2002; Friese and Fugger,
2005). CD8+ T cells are more numerous than CD4+ T cells
in MS plaques and they exhibit an oligoclonal expansion
which is noticeable in MS plaques (Babbe et al., 2000) and
in the CSF of MS patients (Jacobsen et al., 2002). There is
an enrichment of highly differentiated (CCR7-) CD8+
T cells in the CSF of patients with early MS (Jilek et al.,
2007b), suggesting that these cells are activated and antigen-
driven.
Since both EBV and CD8+ T cells are involved in MS, we
decided to study the EBV-specific CD8+ T cells in MS on a
large cohort of patients at different stages of the disease, as
well as patients with other neurological diseases and healthy
subjects. To avoid a bias, we performed a comprehensive
study of the virus-specific cellular immune response in
this cohort, testing for CD4+ as well as for CD8+ T cells.
In order to discriminate between a specific response against
EBV and an aspecific immune hyperactivation phenomenon
in relation with MS, we tested, in the same cohort, the
responses against cytomegalovirus (CMV), which, like EBV,
is a herpes virus that can establish latent infections, and is
neurotropic. However, contrary to EBV, it has neither
convincingly been associated with MS, nor is thought to
play a deleterious role in the disease (Ascherio et al., 2001;
Buljevac et al., 2005).
Material and Methods
Patients and study subjects
Since June 2004, we enrolled a total of 164 study subjects, includ-
ing 35 patients with a clinically isolated syndrome (CIS),
31 patients with relapsing–remitting MS (RR-MS), 24 with
secondary-progressive MS (SP-MS), 18 with primary-progressive
MS (PP-MS), 35 patients with other neurological diseases and
21 healthy control subjects. Patients with MS and those with
other neurological diseases were treated in our Department of
Neurology. They were enrolled consecutively and were followed
up clinically to December 31, 2007. This study was accepted by
our institution’s ethical commission and all subjects gave their
written consent according to review board guidelines. At the time
of enrolment, the diagnosis of MS was made using the criteria of
McDonald (McDonald et al., 2001; Polman et al., 2005).
CIS was defined by the presence of: a first neurological event
consistent with MS; compatible brain/spinal magnetic resonance
imaging (MRI); compatible CSF; exclusion of an alternate diag-
nosis. To rule out other neurological disease than MS, all CIS
patients had complete blood count, electrolytes, kidney and renal
function, erythrocyte sedimentation rate, C-reactive protein, TSH,
B12 and folates, serology for syphilis, Lyme disease and HIV,
immunological markers (anti-nuclear antibody, rheumatoid factor,
anti-nucleoprotein antibodies and anti-neutrophil cytoplasmic
antibodies and protein electrophoresis). CIS patients also had a
CSF evaluation including leukocyte count and differentiation,
glucose level and blood-brain barrier function. To detect the
presence of a putative intrathecal synthesis of oligoclonal IgG, we
performed isoelectric focusing (IEF) on the CSF and homologous
serum on agarose gels followed by immunoblotting. If an
infectious disease of the CNS was suspected, microbial serologies
and PCR were performed in the blood and the CSF to rule it out.
Brain MRIs were performed in all CIS patients, and spinal
cord MRI or visual evoked potentials in selected cases. During
follow-up of CIS patients, MS (RR form) was confirmed in 18/35.
However, since at the time of our assays, these 18 patients
presented with a CIS, they were kept in the CIS category. Of the
17 remaining CIS patients, 10/15 had an intrathecal synthesis of
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IgG (two missed the LP), 13/17 displayed typical MRI lesions of
MS and eight fulfilled Barkhof criteria (Barkhof et al., 1997). The
five patients without intrathecal synthesis of IgG had brain lesions
typical of MS. Out of 35 control patients with other neurological
diseases, 25 had a lumbar puncture, which was inflammatory in
four (55 cells/ml).
Inflammatory mechanisms predominate in the pathogenesis of
CIS and RR-MS, whereas neuro-degenerative ones are more
important in SP- and PP-MS (Noseworthy et al., 2000; Vukusic
and Confavreux, 2003). Thus, we analysed some of our results
by grouping CIS and RR-MS patients on one side and SP- and
PP-MS on the other side, under the names of ‘inflammatory MS’
and ‘progressive MS’, respectively.
None of the study subjects had received corticosteroids within
the 3 months prior to enrolment. Out of the 31 RR-MS patients,
10 were on interferon-b treatment and 9 of these 10 patients were
relapsing at the time of the assay. One SP-MS was on interferon-b
treatment and relapsing at the time of the assay. Patients were
considered as relapsing if a relapse had started54 weeks prior to
the blood sample draw. Human leucocyte antigen (HLA) class I
(A and B) typing was performed in 126/164 (77%) study subjects.
Clinical data of our cohort of 164 study subjects are given in
Table 1.
Isolation of peripheral blood mononuclear
cells (PBMC)
PBMC were isolated by density gradient centrifugation on Ficoll-
Hypaque (Amersham Biosciences, Otelfingen, Switzerland) and
either resuspended in RPMI (Invitrogen, Basel, Switzerland) for
immediate use or frozen in freezing medium, as composed of 90%
fetal calf serum (FCS; Invitrogen) and 10% dimethylsulfoxide
(Sigma, Buchs, Switzerland), and stored in liquid nitrogen for
further analysis.
Virus-specific cellular immune response:
distinction between virus-specific CD4+
and CD8+ T-cell responses
To elicit virus-specific CD4+ or CD8+ T-cell responses, PBMC
were stimulated with purified viral lysates (ABI Inc., Columbia,
MD, USA) or pools of known immunodominant eight- to fifteen-
mer peptide viral epitopes (SynPep Corporation, Dublin, CA,
USA), respectively. For EBV, there were 18 nine- or ten-mer
peptide epitopes, known to elicit CD8+ T cells, restricted by 10
HLA class I alleles, and including epitopes of lytic as well as latent
proteins. For CMV, there were 34 eight- to fifteen-mer peptide
epitopes, known to elicit CD8+ T cells, restricted by 13 HLA class
I alleles, including epitopes of the pp65, pp150 and IE1 proteins
(Supplementary Table 1).
To verify that viral lysates and CD8+-restricted T-cell peptide
epitopes indeed elicited CD4+ and CD8+ T cells, respectively,
we performed intracellular cytokine staining assay (ICS) in a
subset of 24 study subjects, including eight patients with inflam-
matory MS (CIS or RR-MS); eight with progressive MS (SP- or
PP-MS); four with other neurological diseases and four healthy
controls. Two million cells were resuspended in RPMI-10% fetal
calf serum (FCS), stimulated for 18 h with viral lysate or viral
CD8+-restricted peptide epitope pools at 1 mg/ml and stained with
CD3-FITC, CD4-PerCP-Cy5.5, CD8-Pacific Blue and IFN-g -APC
(all from Becton Dickinson, Franklin Lakes, NJ, USA). Data were
acquired on a LSRII flow cytometer and analysed using FlowJo
Software (Tree Star Inc., Ashland, OR, USA).
Detection of viral-specific interferon-c-secreting
T cells
To detect EBV- or CMV-specific activated T cells secreting IFN-g,
we used an enzyme linked immunospot (ELISPOT) assay, such as
we and others have previously described it (Dutoit et al., 2005;
Jilek et al., 2007a). Briefly, 200 000 PBMC were incubated in
quadruplicates in the presence of viral lysates or pools of viral
CD8+-restricted peptide epitopes at a concentration of 1 mg/ml.
Peptide-free medium and phyto-hemagglutinin lectin (PHA-L)
(5mg/ml) served as negative and positive controls, respectively.
Responses were expressed as net spot-forming cells (SFC) per 106
PBMC. The assay was considered experimentally valid if the SFC,
in the absence of peptide, was lower than 50 per 106 cells and if,
in the presence of peptide, the SFC was higher that 50 per 106 cells
and at least 3-fold higher than the background levels. Background
values corresponding to medium-stimulated PBMC were sub-
tracted from the data before analysis.
Table 1 Clinical data of the 164 patients enrolled
Age at blood
draw in yearsa
Delay between
disease onset and
study entrance in yearsa,b
EDSS scorea Patients in
relapse
Number of MS
diagnosis subsequently
confirmed
Inflammatory MS (n=66)
CIS (35) 3914 0.41.2 2 0.8 9 18 (follow-up 2.4 0.9 years)
RR-MS (31) 417 8.2 6.7 2.5 0.8 19 n/a
Progressive MS (n=42)
SP-MS (24) 5716 14.914.3 61.9 2 n/a
PP-MS (18) 55 7 5.6 5.4 3 0.8 0 n/a
Control subjects (n=56)
OND (35) 39 20 0.41.0 n/a n/a n/a
HC (21) 3510 n/a n/a n/a n/a
aNumbers represent the median  inter-quartile range. bStudy entrance corresponded to the diagnostic procedure including drawing of
blood sample.OND=other neurological diseases. HC=healthy controls.
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Detection of virus-specific proliferatingT cells
To determine the presence of T cells proliferating specifically
against a given viral antigen, we performed proliferation assays
(PAs) (Jilek et al., 2007a). Briefly, upon isolation, 200 000 PBMC
were plated in quadruplicate in 96-well plates (Corning Life
Science, Schiphol-Rijk, Netherland) in RPMI-5% human AB
serum (Inotech, Dottikon, Switzerland) and stimulated with viral
lysates or pools of viral CD8+-restricted peptide epitopes at a
concentration of 1 mg/ml. Peptide-free medium served as nega-
tive control and PHA-L (Calbiochem, Dietikon, Switzerland) at
5 mg/ml as positive control. Cells were incubated for 5 days at 37C
and then pulsed overnight with 1 mCi/well methyl-[3H]thymidine
(Hartmann Analytic, Braunschweig, Germany). After harvesting,
nuclear incorporation of radioactivity was measured in a scintil-
lation beta counter (Topcount, Zurich, Switzerland). Proliferation
responses were calculated as stimulation index (SI), as determined
by the mean ratio of antigen-stimulated counts per minute (cpm)
over background cpm. Patients with SI lower than 4.0 were
considered as non-responding.
Analysis of the data of the cellular immune assays
We performed the eight cellular immune response assays (namely,
PA with EBV/CMV lysate; PA with pools of EBV/CMV CD8+-
restricted T-cell peptide epitopes; ELISPOT with EBV/CMV
lysates; ELISPOT with pools of EBV/CMV CD8+-restricted T-cell
peptide epitopes) in as many study subjects as possible. However,
some of these subjects could not have all those eight assays, which
was due either to limited amount of PBMC or to a mismatch
between HLA class I typing of the study subject and alleles repre-
sented in the pool of viral CD8+-restricted T-cell peptide epitopes,
such as explained hereafter.
If a given patient had not, at least, one HLA class I allele
in common with the alleles represented in the pool of viral CD8+
T cell-restricted peptide epitopes, we excluded this patient from
the analyses for the corresponding assay. Since there were some
differences in the HLA class I-restriction between the pools of EBV
and CMV (Supplementary Table 1), some patients could have
determination of their CD8+ T-cell response for one virus, but
not for the other, depending on their HLA class I typing.
In 38/164 (23%) study subjects, HLA class I typing could not
be determined. In these 38 subjects, the results of viral lysate
stimulation could still be validated since viral lysates elicit CD4+
and not CD8+ T cells. Regarding stimulation with the pools of
CD8+-restricted peptide epitopes, in order to be able to gather
information on these patients, we applied the following procedure:
(i) if both PA and ELISPOT assay were negative for a given virus
as tested by the corresponding pool of CD8+-restricted peptide
epitopes, we did not count this result as it was not possible to
determine whether this negative result was due to HLA class I
mismatch between the patient and the pool of viral peptide epitopes
or due to a true absence of CD8+ T-cell response against the virus in
question; (ii) however, if for a given virus, PA and/or ELISPOT were
positive, the results of both assays were validated, as this positivity
provided evidence that there was at least one patient HLA class I
allele represented in the pool of CD8+-restricted peptide epitopes.
Viral-specific humoral immune response
To determine EBV and CMV seropositivity in our cohort, 2-fold
diluted plasma in phosphate-buffered saline from patients were
analysed for the presence of IgG against the EBV antigens viral
capsid antigen (VCA) and EBNA-1 and against the CMV antigen
pp65. Classical enzyme-linked immunosorbent assay (ELISA) was
performed according to manufacturer instructions (Biotest,
Dreieich, Germany). Samples were considered to be positive for
(i) EBV VCA and EBNA-1 IgG if the OD measured was greater
than negative control +0.2 OD; (ii) CMV antigen pp65 IgG if the
OD measured was greater than negative control +0.3 OD.
To obtain a more comprehensive profile of the EBV-specific
humoral immune response in a selected subset of MS patients, we
used a bead-based multiplexed immunoassay [Luminex; (Vignali,
2000)] and the Athena Multi-Lyte IgM and IgG test system
(Teomed AG, Greifensee, Switzerland). We have recently observed
in a comparison study that this assay is more sensitive than an
immunofluorescence assay (EBNA ACIF) for anti-EBNA-1 detec-
tion (P. Meylan, unpublished data). Specifically, we checked for
anti-VCA IgM and anti-EA IgG, markers of primo-infection or
recent reactivation (Buisson et al., 1999), and anti-VCA IgG and
anti-EBNA-1 IgG, markers of past EBV infection. Data were
expressed as arbitrary units (AU)/ml. Samples were considered
as positive when the resulting measure was 5120 AU/ml. We
studied 40 patients, including 25 patients with an inflammatory
form of MS and 15 with a progressive one, who were chosen
among those with a high (22), respectively a low (18) IFN-g
secreting EBV-specific CD8+ T-cell response as measured by
IFN-g secretion, 200 SFC/106 cells being the cut-off.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). We corrected all the
data for age, using linear regression analysis over the total cohorts
of EBV- and CMV-infected subjects (MS and controls). Indeed, in
this study, the subjects were not matched for age (Table 1).
Another reason to perform this correction was that EBV- and
CMV-specific T-cell responses have been shown to increase with
age (Khan et al., 2002; Stowe et al., 2007).
Subsequent analysis were performed on these age-corrected data
sets. The differences among the six groups of study subjects were
tested using Kruskal–Wallis test for non-normally distributed
variables. The difference between two groups was tested using
the non-parametric Mann–Whitney ranked test, whereas paired
samples were tested with the non-parametric Wilcoxon ranked
test. Correlations were analysed using the Spearman’s rank test.
rs denotes the correlation coefficient of Spearman’s rank test.
A P50.05 was considered significant.
Results
The rate of viral infection in the whole
cohort is higher for EBV than CMV
We found that 139/159 (87%) and 63/149 (42%) study
subjects displayed evidence of a cellular immune response
against EBV and CMV, respectively, as revealed by prolif-
eration and/or IFN-g secretion by CD4+ and/or CD8+ T
cells (Fig. 1, left panels). Thus there were 20/159 (13%)
and 86/149 (58%) study subjects who had no EBV- or
CMV-specific T-cell responses of any sort, respectively.
In order to determine if the absence of virus-specific
cellular immune response in those study subjects was due
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to hyporesponsiveness or genuine seronegativity, we per-
formed an ELISA to detect anti-EBV (VCA and EBNA-1) and
anti-CMV (pp65) IgG responses. We found that among study
subjects with a negative viral response as assessed by the
‘cellular assays’ (PA/ELISPOT), 19/20 patients had EBV-
specific antibodies, contrasting with only 13/86 study subjects
who had CMV-specific antibodies (Fig. 1, middle panels).
Thus, we could determine that, overall, the rate of CMV
infection was much lower (76 out of 149; 51%) than the rate
of EBV infection (158 out of 159; 99%, P50.0001), in
accordance with literature (Harari et al., 2004; Haahr and
Hollsberg, 2006). However, for a given virus, there was no
difference in the rate of infection between categories of study
subjects (Fig. 1, right panels).
ICS performed in 24 study subjects confirmed that viral
lysates and pools of 8- to 15-mer peptide epitopes elicited
CD4+ and CD8+ T cells, respectively (Supplementary
Figure 1).
High activation of EBV-specific CD8+
T cells in patients with CIS
Using ELISPOT assay, we found that the stimulation of
PBMC with pools of CD8+-restricted T-cell peptide
epitopes of EBV—but not CMV—induced an age-corrected
higher frequency of IFN-g secreting CD8+ T cells in
patients with CIS as compared to all other categories of
study subjects (P= 0.002), i.e. patients with RR-MS
(P= 0.02), SP-MS (P= 0.0001), PP-MS (P= 0.009), patients
with other neurological diseases (P= 0.003) and control
subjects (P= 0.002) (Fig. 2A).
In contrast, the magnitude of CMV-specific IFN-g
secreting CD8+ T cells was similar between the groups of
study subjects (P40.9, Fig. 2B). Moreover, contrary to
what we had observed with viral-specific CD8+ T cells,
PBMC stimulation with EBV lysate induced no difference
in terms of IFN-g secretion by CD4+ T cells between
categories (P40.5). The same was true for CMV (P40.1,
results not shown).
Looking at the proliferative capacities of EBV- and CMV-
specific T cells, we found that CD4+ T cells were always
more prone to proliferate than CD8+ T cells, whichever was
the stimulating virus. There was no difference in the SIs
between the six groups of study subjects, either for EBV or
CMV, and either for CD4+ or CD8+ T cells (P40.3, results
not shown).
The more recent the clinical MS onset,
the higher the level of IFN-c secretion by
EBV-specific CD8+ T cells
Performing a linear regression analysis over the cohort of
all MS patients, including CIS, we found that the EBV-
specific IFN-g secreting CD8+ T-cell response was inversely
proportional to the interval between disease onset and our
assay: the shorter the interval, the higher the response
(rs =0.30, P= 0.003, Fig. 2C). Confirming the above
results, we found that EBV-specific CD8+ T-cell responses
decreased in 12/13 patients with CIS followed prospectively
for 1.0 0.2 years (P= 0.0024; Fig. 2D). However, when we
compared, among the category of patients with inflamma-
tory MS, the results of relapsing versus remitting patients,
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Fig. 1 Viral-specific cellular and humoral immune response and overall rate of infection in the cohort. The cellular immune response
was assessed by PA and ELISPOT, while the humoral response was determined by detecting EBV- or CMV-specific antibodies such
as described in Material and Methods section.
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Fig. 2 Elevated frequency of IFN-g secreting EBV-specific effector CD8+ T cells in patients with CIS. IFN-g secretion was assessed by
ELISPOTand the magnitude of responding CD8+ T cells calculated as SFC/106 PBMC. (A) EBV- and (B) CMV-specific CD8+ T-cell responses
are shown. Each dot represents one patient and the horizontal bars correspond to the median values. (C) In the MS patient cohort
(92 patients; CIS, RR-, SP-, PP-MS), the magnitude of EBV-specific CD8+ T-cell response was inversely correlated with the interval between
MS onset and assay. (D) In these13 patients with CIS, the secretion of IFN-g by EBV-specific CD8+ T cells was assessed on two time-points
separated by a median of 1.0 0.2 years. (E) Patients with inflammatory MS (CIS and RR-MS) were divided into relapsing (n=27) and
remitting patients (n=27). EBV-specific CD8+ T cell responses were plotted accordingly.Virus-specific CD8+ T cell responses were
expressed as spot forming (i.e. IFN-g secreting) cells (SFC)/106 PBMC. SFC; rs, Spearman’s coefficient r; NS, P40.05; P50.05; P50.01;P50.001.
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we found no difference between both groups, suggesting
that the degree of activation of EBV-specific CD8+ T cells
was not dependent on the degree of activity of MS (P40.3,
Fig. 2E).
Correlation between anti-EBNA-1 antibodies
and EBV-specific CD8+ T cells
Using the flow cytometry-based multiplexed quantitative
serological assay [Luminex Technology (Vignali, 2000)],
we found that anti-VCA IgG and anti-EBNA-1 IgG, but not
anti-VCA IgM, and only rarely anti-EA IgG, were detectable
in MS patients, suggesting that the increased EBV-specific
CD8+ T-cell response was not attributable to recent infec-
tion or reactivation (Fig. 3A). Nevertheless, six MS patients
had elevated anti-EA IgG, suggesting that in these patients a
recent reactivation of EBV was possible. Interestingly, all
these six MS patients had a strong EBV-specific CD8+
T-cell response (4150 SFC/106 cells). The magnitude of
anti-EBNA-1, but not anti-VCA IgG, response was
moderately correlated with the one of EBV-specific CD8+
T cells secreting IFN-g in patients with inflammatory MS
(rs = 0.38, P= 0.016, Fig. 3B), but not in patients with
chronic MS (P40.4). Finally, in contrast to what we had
found for IFN-g-secreting CD8+ T cells, there was no
correlation between the level of anti-EBNA-1 or anti-VCA
IgG and the interval between MS onset and our assay.
Discussion
We found that there was a higher EBV-specific CD8+ T-cell
response, IFN-g-mediated, in patients with CIS as com-
pared to patients with all other forms of MS, patients with
other neurological diseases and control subjects. In contrast,
no difference between categories of study subjects was
found in terms of EBV-specific CD4+ T-cell response.
We did not find either any difference in the CMV-specific
cellular immune response or the different categories of
study subjects for both CD4+ and CD8+ T cells. These
results suggest that the increased EBV-specific CD8+ T-cell
response observed in patients with CIS may reflect a
specific role of EBV in MS rather than be a mere surrogate
marker of non-specific immune hyperactivation. In both
the cross-sectional and longitudinal parts of this study,
we found that the more recent was the clinical onset of MS,
the higher was the EBV-specific CD8+ T-cell response.
However, there was no difference between relapsing and
remitting patients with inflammatory MS (CIS and
RR-MS). Several reports have consistently shown that
viral infections are associated with relapses (Edwards
et al., 1998; Buljevac et al., 2002; Correale et al., 2006).
In this context, the role of EBV is debated. Indeed, an
increase of anti-EA antibodies and detection of serum
EBV DNA has been shown in relapsing MS patients by
some authors (Wandinger et al., 2000), but not by others
(Buljevac et al., 2005). Altogether, our data suggest that if
EBV plays a role in the pathogenesis of MS, it would rather
be as a trigger of the disease itself than of relapses.
The higher EBV-specific CD8+ T-cell response we found
in patients with CIS is in accordance with the trend
reported by Lunemman et al. in a smaller group of MS
patients (Lunemann et al., 2006). In contrast, Gronen et al.
did not find different IFN-g secretion in CD8+ T cells
between MS patients and control subjects (Gronen et al.,
2006). Several points can be raised in order to explain these
differences. First, in our study none of the CIS patients
received immunomodulatory treatment that may potentially
modify viruses-specific cellular immune responses. Second,
we used a pool of 18 different EBV peptide epitopes
restricted by 10 HLA class I alleles, while Gronen et al.
focused on HLA B7-restricted CD8+ T-cell peptide epitopes
(Gronen et al., 2006), thus missing the CD8+ T-cell
responses mediated by other HLA class I alleles. Third, we
enrolled a large proportion of patients with CIS, a category
which was not included in Gronen’s study. Yet, it is
precisely in this group that we found the highest EBV-
specific CD8+ T-cell response.
To determine their stage of EBV infection, we performed
serologies in a large subset of our MS patients. Using the
sensitive Luminex technology, we found anti-VCA and
anti-EBNA-1 IgG, but not anti-VCA, and only rarely anti–
EA IgG, a pattern indicating that the EBV primary infection
was remote, such as it has already been reported by others
(Goldacre et al., 2004). Of interest, such as reported by
Buljevac and colleagues, we found elevated anti-EA IgG in
a small subgroup of patients, suggesting a recent EBV
reactivation (Buljevac et al., 2005). Of note, these patients
also had a strong CD8+ T-cell response. However, this
subgroup of patients was too small to draw definitive con-
clusions on the reactivation of EBV in these MS patients.
Furthermore, while anti-EBNA-1-specific antibodies (but
not anti-VCA antibodies) correlated moderately with EBV-
specific CD8+ T cells in patients with inflammatory MS,
EBV-specific CD8+ T cells were a better marker of early MS
than anti-EBNA-1-specific antibodies as the latter were also
increased in progressive forms of MS.
Whereas the overall rate of EBV infection in our whole
cohort was 99%, it was only 51% for CMV, without
differences between MS patients and control subjects. These
findings do not support a specific relationship between
MS and CMV—as opposed to MS and EBV—and are in
agreement with previous work from Buljevac et al. These
studies showed that, whereas there was a higher percentage
of antibodies specific for EBV EA in MS patients (48%) as
compared to controls (25%), CMV-specific antibodies were
detected at a similar rate in both categories (Buljevac et al.,
2005). Zivadinov et al. even suggested that CMV might
have a protective role as CMV-positive MS patients were
found to have lower T2-lesion loads and higher parenchy-
mal brain fraction than CMV-negative MS patients
(Zivadinov et al., 2007).
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An infectious etiology of MS, in particular a viral one,
has been evoked a long time ago (Marie, 1886), but the
Koch postulate has never been fulfilled for any studied
microbes in MS (Lipton et al., 2007). Nevertheless, even if
MS may not be an infectious disease, strictu sensu, an
infectious agent might still play an important role in the
pathogenesis of this disease. Precisely, it has been hypoth-
esized that, in genetically predisposed individuals carrying
a potentially harmful virus, the anti-viral immune response
can cross-react against auto-antigen epitopes (Correale
et al., 2006). In particular, EBV-specific CD4+ T cells
present in the blood or the CSF of MS patients can
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Fig. 3 Anti-EBNA-1 IgG are correlated with the secretion of IFN-g by CD8+ T cells in inflammatory MS patients. (A) Sera from 40
selected patients were collected and assayed for anti-VCA IgM, anti-EA IgG, anti-VCA IgG and anti-EBNA-1 IgG as described in Material
and Methods section. Data are presented as arbitrary units/ml. Each dot represents one patient, the horizontal bars correspond to the
median values and a dotted line determines the threshold for positive responses. (B) In patients with inflammatory MS (CIS/RR-MS), anti-
EBNA-1 IgG were moderately correlated with the IFN-g secretion by EBV-specific CD8+ T cells. rs, Spearman’s coefficient r. NS, P40.05.
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cross-react with myelin basic protein (MBP) (Lang et al.,
2002; Holmoy et al., 2004). We reported recently that an
acute EBV infection could trigger a strong myelin
oligodendrocyte glycoprotein (MOG)-specific cellular and
humoral immune response in a patient suffering from a
severe post-EBV encephalopathy (Jilek et al., 2007a). These
data suggest that a mechanism of molecular mimicry
between EBV and myelin antigen might take place in
patients infected with EBV. Another recent paper adds an
interesting piece to the story of MS and EBV: Serafini and
colleagues have found EBV-infected B cells in the meninges,
in the perivascular space and in the demyelinated lesions of
patients with different categories of MS, inflammatory as
well as progressive ones. Such EBV-infected B cells were not
found in patients with inflammatory other neurological
diseases (Serafini et al., 2007). An expansion of cytotoxic
CD8+ T cells, as demonstrated by the expression of IFN-g,
perforin and CD107a, was present at the sites of EBV-
infected B cells, strongly suggesting that the latter cells were
recognized and attacked by activated CD8+ T cells in the
CNS. Our data showing that there is an increased secretion
of IFN-g by EBV-specific CD8+ T cells in patients with
early MS are consistent with these findings. The decline in
the frequency of EBV-specific CD8+ T cells in the blood
observed over time may reflect either a control of EBV
reactivation or a selective migration of CD8+ T cells in the
site of MS lesions (Serafini et al., 2007). In this regard, it
has been shown a preferential concentration of CD8+ T
cells in MS lesions (Babbe et al., 2000). The possibility that
this decrease in frequency of EBV-specific CD8+ T cells
result from virus-induced T cell exhaustion and/or
dysregulation should also be taken into account
(Klenerman and Hill, 2005).
Supplementary material
Supplementary material is available at Brain online.
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